DKK 728.0
(2.82%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 114.93 Million DKK | 17.26% |
2022 | 97.74 Million DKK | -41.08% |
2021 | 165.88 Million DKK | 79.62% |
2020 | 92.35 Million DKK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 35.81 Million DKK | 19.68% |
2024 Q2 | 35.81 Million DKK | 0.0% |
2023 Q1 | 27.54 Million DKK | 2.65% |
2023 FY | 114.61 Million DKK | 17.26% |
2023 Q3 | 29.92 Million DKK | 8.62% |
2023 Q2 | 27.54 Million DKK | 0.0% |
2023 Q4 | 29.92 Million DKK | 0.0% |
2022 Q2 | 22.03 Million DKK | 0.0% |
2022 Q1 | 22.03 Million DKK | 0.0% |
2022 FY | 97.74 Million DKK | -41.08% |
2022 Q3 | 26.83 Million DKK | 21.77% |
2022 Q4 | 26.83 Million DKK | 0.0% |
2021 FY | 165.88 Million DKK | 79.62% |
2020 FY | 92.35 Million DKK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ALK-Abelló A/S | 3.03 Billion DKK | 96.213% |
Bavarian Nordic A/S | 4.52 Billion DKK | 97.458% |
Genmab A/S | 16.24 Billion DKK | 99.293% |
Novo Nordisk A/S | 196.49 Billion DKK | 99.942% |
Orphazyme A/S | - DKK | -Infinity% |
Pharma Equity Group A/S | -480 Thousand DKK | 24045.0% |
Zealand Pharma A/S | 323.61 Million DKK | 64.484% |